Use of tissue culture in predictive testing of drug sensitivity in human ovarian cancer. Correlation between in vitro results and the response in vivo

Neoplasma · 1982 · vol. 29(3) , pp. 309–14 · PMID:7133226
Other public-domain-us
View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-09-13 ⓘ

An in vitro model measuring 3H-thymidine incorporation predicted in vivo sensitivity to Melphalan and Adriamycin with 80% accuracy in 20 patients with advanced ovarian cancer.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The present work uses an in vitro test model to measure the sensitivity of human ovarian cancer cells to Melphalan and Melphalan combined with Adriamycin. With this model we studied the possible correlation between the in vitro results and the response to these cytostatic drugs in vivo. Cancer cells from 20 patients with advanced ovarian cancer were tested. The in vitro effects of the drugs were measured as differences in incorporation of labeled 3H-thymidine in drug containing tubes and in control tubes. The effects of the drugs on the different cancer cells varied greatly from strong sensitivity to resistance. In vitro and in vivo results were compared one year after start of patient treatment. The overall agreement was 16/20, 80%. The in vitro method thus estimates a tumor cell characteristic which has a biological meaning also in in vivo conditions.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Doxorubicin Melphalan Ovarian Neoplasms Adenocarcinoma Adenocarcinoma Adenocarcinoma Carcinoma Carcinoma Carcinoma Cells, Cultured Cells, Cultured Doxorubicin Doxorubicin Doxorubicin Drug Evaluation, Preclinical Drug Evaluation, Preclinical Drug Therapy, Combination Drug Therapy, Combination Endometriosis Endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-25T09:32:14.900964+00:00
pubmed
last seen: 2026-10-08T21:58:37.372514+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine